SCIg60® Secures Expanded Indications for Use
EMED Technologies today announced that the SCIg60® Infusion System has secured expanded FDA-cleared indications for use, further establishing it as the only mechanical pump infusion system cleared in the U.S. for subcutaneous infusion of immunoglobulin (SCIg).
The expanded indications now include subcutaneous infusion of Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, manufactured by CSL Behring — building on the SCIg60's existing position as the first and only syringe infusion system cleared by the FDA specifically for subcutaneous infusion of immunoglobulin solutions.
The expansion of indications resulted from EMED's positive interaction with the FDA in the context of increasingly stringent regulations for infusion devices. The SCIg60® remains a cornerstone of EMED's strategy to deliver patient-centric infusion solutions for clinicians and patients managing chronic conditions.
For more information about the SCIg60® and EMED's full portfolio, visit emedtc.com.
About EMED
EMED Technologies is an industry leader in the design, manufacture, and distribution of cutting-edge medical devices. For two decades, EMED Technologies has worked with clinicians, inventors, and medical companies to develop innovative medical products. Today, we are proud that both patients and clinicians can benefit from the fruits of our labor because we offer a wide variety of products and services that improve therapies and enhance clinical benefits. With our dynamic team of professionals, EMED continues to work with clinicians to understand their requirements and improve upon available technologies. In addition to novel technology, EMED is proud to offer licensing agreements for patented and proprietary technologies.
Media contact
For media inquiries, please contact info@emedtc.com.